Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

A new prognostic index (CLIPI) stratifies risk in advanced cutaneous lymphomas: Associations with treatment pathways, quality of life and survival

Abraham Bashir, Pietro Quaglino, Felicity Evision, Youn-H Kim, Julia Scarisbrick

Blood (2025) 146 (Supplement 1): 559.

https://doi.org/10.1182/blood-2025-559

Published: 2025

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas

Safa Najidh, Joseph Cleveland, Ryan Burke, Armando Bastidas Torres, Alexa Kwang, George Duran, Yonatan Cooper, Ilan Kirsch, Bing Zhang, Youn-H Kim, Michael Khodadoust

Blood (2025) 146 (Supplement 1): 5431.

https://doi.org/10.1182/blood-2025-5431

Published: 2025

Journal Articles

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Richard Miller, Ryan Wilcox, John Reneau, Costas Yannakou, Won Seog Kim, Tatyana Feldman, Youn-H Kim, Michael Khodadoust, Dejan Radeski, Robin Gasiorowski, Dok Hyun Yoon, Yuqin Song, Andrew Hotson, Suresh Mahabhashyam

Blood (2025) 146 (Supplement 1): 778.

https://doi.org/10.1182/blood-2025-778

Published: 2025

Journal Articles

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Blood (2025) 146 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2025-1875

Published: 2025

Journal Articles

Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas

Blood (2025) 146 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2025-1872

Published: 2025

Journal Articles

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Julia J. Scarisbrick, Pietro Quaglino, Sean Whittaker, Martine Bagot, Emmanuella Guenova, Evangelia Papadavid, Henry Miles Prince, Jose A. Sanches, Denis R. Miyashiro, Octavio Servitje, Christiane Querfeld, Oleg Akilov, Arvind Arumainathan, Luke Bennett, Maxime Battistella, Kim Benstead, Emilio Berti, Marie Beylot-Barry, Anne-Marie Busschots, Richard Cowan, Reinhard Dummer, Giles Dunnill, Teresa Estrach, Felicity Evison, Abraham Bashir, Larisa Geskin, Ale Gru, Joan Guitart, Melba C. Herrera, Emillia Hodak, Steve Horwitz, Constanze Jonak, Claus-Detlev Klemke, Robert Knobler, Pam Mckay, Marta Marschalkó, Cesare Massone, Rubeta Matin, Christina Mitteldorf, Robert Novoa, Pablo Ortiz-Romero, Nicola Pimpinelli, Ramon M. Pujol, Annmari Ranki, Liisa Vakeva, Kerri E. Rieger, Rudolf Stadler, Franz Trautinger, Johanna Latzka, Maarten Vermeer, Rachel Wachsmuth, Sophie Weatherhead, Ulrike Wehkamp, Marion Wobser, Youn H. Kim

Blood (2025) 146 (14): 1687–1692.

https://doi.org/10.1182/blood.2025029628

Published: 2025

Includes: Supplemental data

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C. Kwang, George E. Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N. Bastidas Torres, Erica B. Wang, Melba Herrera, Tarek I. Bandali, David M. Kurtz, Youn H. Kim, Michael S. Khodadoust

Blood (2025) 145 (3): 311–324.

https://doi.org/10.1182/blood.2024024817

Published: 2025

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Leyla Bojanini, Melba Herrera, Shufeng Li, Tarek Bandali, Nicole Y. Xu, Abdullah A. Ahmed, Michael S. Khodadoust, Youn H. Kim

Blood (2024) 144 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2024-198783

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Tatyana Feldman, Hun Ju Lee, Gizelle Popradi, Graham P. Collins, Daniel Morillo, Ming Jin Yan, Tara Chen, Youn H. Kim

Blood (2024) 144 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2024-200265

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Michi M Shinohara, Youn H. Kim, Kevin Molloy, Pietro Quaglino, Julia Scarisbrick, Susan R. Thornton, Kerry Sandilands, Jen E Liu, Annabel Nixon, Angela Williams, Pablo L. Ortiz-Romero

Blood (2023) 142 (Supplement 1): 1704.

https://doi.org/10.1182/blood-2023-188808

Published: 2023

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S. Khodadoust, Eric Mou, Youn H. Kim

Blood (2023) 141 (7): 695–703.

https://doi.org/10.1182/blood.2020008241

Published: 2023

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Eric Mou, Sebastian Fernandez-Pol, Shufeng Li, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 140 (Supplement 1): 6552–6553.

https://doi.org/10.1182/blood-2022-158610

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A new prognostic index (CLIPI) stratifies risk in advanced cutaneous lymphomas: Associations with treatment pathways, quality of life and survival

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only